CAR-T cell therapy has revolutionized blood cancer treatment, but it hits a wall with solid tumors like lung and breast cancer because the engineered immune cells lack the support systems they need to sustain a long-term fight. Scientists at Fred Hutch Cancer Center have discovered a way to give these cells a "portable pit crew"—essentially a built-in refueling station—that could transform how we treat cancers that have resisted immunotherapy for years. Why CAR-T Cells Run Out of Gas Against Solid Tumors Over the past decade, CAR-T cell therapy has been a game-changer for blood cancers. The treatment involves taking a patient's own T cells (immune cells that fight disease) and genetically engineering them with a synthetic molecule called a chimeric antigen receptor (CAR) that acts like a GPS system, guiding the cells straight to cancer cells. The problem? That same GPS focus is a weakness. In natural immune responses, T cells don't work alone. They receive critical support and information from other immune cells, particularly in lymph nodes—small immune organs scattered throughout the body where the immune system "arms up" and builds stamina for long-term battles. But CAR-T cells bypass these training grounds entirely. They head straight for tumors, deliver an initial burst of anti-cancer activity, and then become exhausted—they're sprinters, not marathoners. "The lymph node is the safe spot, where the immune system really arms up. It's the training ground," explains Dr. Shivani Srivastava, an immunologist at Fred Hutch who led the research. "We tend to look at the literature on endogenous T cells and apply it one-to-one to CAR T cells, but we're beginning to understand that CARs are their own immune context. They ignore a lot of the niches that really help sustain T-cell responses". How Scientists Created a Portable Support System In research published in Science Immunology, Srivastava and her team, working with University of Washington MD/PhD student Andrew Snyder, discovered that boosting expression of a gene called c-Jun could equip CAR-T cells with their own portable support system. The c-Jun protein turns on genes that give T cells the "stemness" they need—the ability to self-renew and transform into different types of cells, much like stem cells do. This allows them to seed repeated attacks against tumors while maintaining a long-lived pool of battle-ready cells. The researchers tested this approach in a preclinical mouse model of lung cancer where tumors grew naturally alongside an intact immune system, mimicking how cancer develops in patients. They created CAR-T cells that targeted a protein called ROR1 (found at higher levels in certain tumors) and engineered them to overexpress c-Jun. Initially, the results were disappointing. Boosting c-Jun alone didn't significantly improve how well the CAR-T cells fought tumors. But then came the breakthrough: the c-Jun-overexpressing CAR-T cells showed molecular markers similar to those seen in stemlike T cells found in lymph nodes—cells that are major responders to checkpoint inhibitors, a type of immunotherapy that removes the brakes tumors use to block T cell function. The Game-Changing Combination: CAR-T Plus Checkpoint Inhibitors When Snyder and Srivastava added a checkpoint inhibitor to the c-Jun-overexpressing CAR-T cells, the results were dramatic. After just five days, the number of these cells within tumors had increased more than tenfold. Boosted by the checkpoint inhibitor, they achieved near-complete tumor clearance. In contrast, checkpoint inhibitors had no effect on CAR-T cells lacking the c-Jun enhancement. This discovery solves a puzzle that has frustrated researchers for years. Checkpoint inhibitors work by blocking proteins like PD-1 and PD-L1 that normally prevent T cells from attacking healthy cells. Scientists have tried adding checkpoint inhibitors to CAR-T cells before, but the results were inconsistent and puzzling—especially since CAR-T cells were already PD-1 positive and tumors had high levels of PD-L1. The new research reveals why: CAR-T cells need to be "rewired" with stemlike qualities before they can fully respond to checkpoint inhibitors. Once they have that rewiring, the checkpoint inhibitor becomes the key that unlocks the portable pit crew's full potential. How This Discovery Could Expand Cancer Treatment Options Checkpoint inhibitors are already approved to treat a wide range of cancers beyond blood cancers. The FDA has approved these immunotherapies for patients with: - Skin Cancers: Melanoma, basal cell skin cancer, and cutaneous squamous cell cancer - Lung and Respiratory Cancers: Lung cancer and mesothelioma - Gastrointestinal Cancers: Colorectal cancer, esophageal cancer, stomach cancer, and liver cancer - Genitourinary Cancers: Bladder cancer, kidney cancer, and cervical cancer - Other Solid Tumors: Head and neck squamous cell cancers, endometrial cancer, ovarian cancer, and bile duct cancer If the CAR-T plus checkpoint inhibitor strategy can be successfully translated to the clinic, it could potentially extend CAR-T therapy's benefits to patients with these solid tumors—a population that has largely been left out of the CAR-T revolution. Steps to Understanding This Emerging Treatment Approach - Understand CAR-T Basics: CAR-T cells are genetically engineered immune cells that target cancer cells directly, but they lack the natural support systems that help regular T cells sustain long-term immune responses in the body - Recognize the Exhaustion Problem: Without access to lymph node-type support, CAR-T cells become exhausted and lose effectiveness against solid tumors, which is why the therapy has worked well for blood cancers but struggled with lung, breast, and other solid tumors - Learn About the c-Jun Solution: Boosting the c-Jun gene rewires CAR-T cells to mimic the stemlike qualities they would normally develop in lymph nodes, making them responsive to checkpoint inhibitors that can then amplify their anti-tumor activity What's Next for Patients? Srivastava emphasizes that this strategy is still several steps away from clinical use. The research reveals basic biological principles that could help improve the design of future cellular immunotherapies, but moving from preclinical mouse models to human trials requires extensive additional work. However, the findings offer hope for a significant gap in cancer treatment. While checkpoint inhibitors alone have transformed care for many solid tumor patients, and CAR-T therapy has revolutionized blood cancer treatment, combining the two approaches with the right cellular engineering could create a powerful new option for patients whose cancers have resisted existing therapies. The research also highlights an important principle: sometimes the most effective cancer treatments aren't about finding a single magic bullet, but rather about understanding how different immune strategies can work together. By giving CAR-T cells the tools to access the support systems they need, scientists may finally unlock their potential against the solid tumors that have remained largely out of reach.
